Cited by CrossRef (12)

  1. Yujin Shin, Haeri Choi, Soo Lim. Comparison betweeen dapagliflozin add-on therapy and insulin dose escalation in patients with uncontrolled type 2 diabetes treated with insulin: DVI study. Diabetes Research and Clinical Practice 2021;175:108843
    https://doi.org/10.1016/j.diabres.2021.108843
  2. Bo Xu, Shaoqian Li, Bo Kang, Jiecan Zhou. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Cardiovasc Diabetol 2022;21
    https://doi.org/10.1186/s12933-022-01512-w
  3. Luke V. Selby, Aslam Ejaz, Stacy A. Brethauer, Timothy M. Pawlik. Fatty liver disease and primary liver cancer: disease mechanisms, emerging therapies and the role of bariatric surgery. Expert Opinion on Investigational Drugs 2020;29:107
    https://doi.org/10.1080/13543784.2020.1721457
  4. Hoda Taheri, Mojtaba Malek, Faramarz Ismail-Beigi, Farhad Zamani, Masoudreza Sohrabi, Mohammad Reza babaei, Mohammad E. Khamseh. Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Adv Ther 2020;37:4697
    https://doi.org/10.1007/s12325-020-01498-5
  5. Eleftheria Galatou, Elena Mourelatou, Sophia Hatziantoniou, Ioannis S. Vizirianakis. Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs. Antioxidants 2022;11:1060
    https://doi.org/10.3390/antiox11061060
  6. Juan Zheng, Ting Chen, Xin Guo, James M. Ntambi, Chaodong Wu. Lipid Signaling and Metabolism. 2022.
    https://doi.org/10.1016/B978-0-12-819404-1.00014-2
  7. Pieter Gillard, Oliver Schnell, Per-Henrik Groop. The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes. Diabetes Research and Clinical Practice 2020;170:108462
    https://doi.org/10.1016/j.diabres.2020.108462
  8. RehabF Abdel-Rahman. Non-alcoholic fatty liver disease: Epidemiology, pathophysiology and an update on the therapeutic approaches. Asian Pac J Trop Biomed 2022;12:99
    https://doi.org/10.4103/2221-1691.338919
  9. Kyung‐Soo Kim, Sangmo Hong, Hong‐Yup Ahn, Cheol‐Young Park. Triglyceride and glucose index is a simple and easy‐to‐calculate marker associated with nonalcoholic fatty liver disease. Obesity 2022;30:1279
    https://doi.org/10.1002/oby.23438
  10. Ronald M. Goldenberg, Vineeta Ahooja, Kristin K. Clemens, Jeremy D. Gilbert, Megha Poddar, Subodh Verma. Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes. Canadian Journal of Diabetes 2021;45:291
    https://doi.org/10.1016/j.jcjd.2020.09.005
  11. Rosemarie Lajara. Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes. Postgraduate Medicine 2019;131:555
    https://doi.org/10.1080/00325481.2019.1670017
  12. Anne Flint, Grit Andersen, Paul Hockings, Lars Johansson, Anni Morsing, Mads Sundby Palle, Thomas Vogl, Rohit Loomba, Leona Plum‐Mörschel. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2021;54:1150
    https://doi.org/10.1111/apt.16608